Related Experiment Video
Updated: May 25, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Targeted therapy of soft tissue sarcomas
Eva Wardelmann1, Jens M Chemnitz, Clemens-Martin Wendtner
1Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Abstract:
Soft tissue sarcomas (STS) are rare mesenchymal cancers with a heterogeneous histology. In terms of oncogenesis, sarcomas may be differentiated into diseases with defined molecular events and sarcomas presenting with complex karyotypes lacking identifiable specific genetic changes or expression profile signatures. The former subtype is amenable to therapy with targeted drugs, especially if the tumor carries a consistent causal mutation occurring early in the disease development. While targeted therapy based on tyrosine kinase inhibition such as imatinib and second generation tyrosine kinase inhibitors plays an important role in the treatment of gastrointestinal stromal tumors (GIST), some progress was also achieved in non-GIST sarcomas. Targeting the PI3 kinase/Akt pathway has been shown to be clinically promising in a diversity of different sarcoma subtypes, and inhibition of the vascular endothelial growth factor (VEGF)/VEGF receptor pathway is of special interest in vascular sarcoma subtypes. MDM2 and p53 seem to be interesting targets for STS, but their role has yet to be defined in further clinical trials. Modification of epigenetic mechanisms, especially deacetylation, might be crucial in other STS subtypes such as translocation-associated entities, but its role has yet to be clinically confirmed. Inclusion of patients in controlled clinical trials combined with a translational research platform is critical for further progress.
Insights
Soft tissue sarcomas (STS) are rare cancers. Targeted therapies show promise for specific subtypes, with ongoing research into pathways like PI3K/Akt and VEGF, and epigenetic modifications.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Soft tissue sarcomas (STS) are rare, heterogeneous mesenchymal cancers.
- STS oncogenesis involves distinct molecular events or complex karyotypes.
- Targeted therapies are effective for STS with specific, early-stage mutations.
Purpose of the Study:
- To review current and emerging targeted therapies for soft tissue sarcomas.
- To highlight promising molecular targets and pathways for STS treatment.
- To emphasize the importance of clinical trials and translational research.
Main Methods:
- Review of current literature on soft tissue sarcoma molecular biology and targeted therapies.
- Analysis of specific molecular pathways implicated in STS oncogenesis.
- Discussion of potential therapeutic targets including tyrosine kinases, PI3K/Akt, VEGF, MDM2/p53, and epigenetic modifiers.
Main Results:
- Tyrosine kinase inhibitors are established treatments for gastrointestinal stromal tumors (GIST) and show progress in non-GIST sarcomas.
- Targeting the PI3K/Akt pathway is clinically promising across various STS subtypes.
- VEGF/VEGFR pathway inhibition is particularly relevant for vascular sarcomas.
- MDM2/p53 and epigenetic modifications (e.g., deacetylation) are potential targets requiring further clinical validation.
Conclusions:
- Targeted therapies offer significant potential for specific soft tissue sarcoma subtypes.
- Further clinical trials are essential to define the role of novel targets like MDM2/p53 and epigenetic modifiers.
- Integrating translational research with clinical trials is critical for advancing STS treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...